OPKO HEALTH INC. - CO

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

25 7 2022 15:05:00 提供 Nasdaq GlobeNewswire

OPKO Health to Present at the 2022 Jefferies Healthcare Conference

02 6 2022 07:00:02 提供 Nasdaq GlobeNewswire

OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

09 5 2022 15:05:01 提供 Nasdaq GlobeNewswire

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

09 5 2022 08:23:34 提供 Nasdaq GlobeNewswire

OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

05 5 2022 15:05:02 提供 Nasdaq GlobeNewswire

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

24 2 2022 15:05:01 提供 Nasdaq GlobeNewswire

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

17 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

03 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

20 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

23 12 2021 07:00:00 提供 Nasdaq GlobeNewswire

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

08 12 2021 07:00:02 提供 Nasdaq GlobeNewswire

OPKO Health Announces the Passing of Director Dr. Richard Lerner

06 12 2021 07:00:02 提供 Nasdaq GlobeNewswire

OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

29 11 2021 07:00:01 提供 Nasdaq GlobeNewswire

OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

28 10 2021 15:15:01 提供 Nasdaq GlobeNewswire

OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

25 10 2021 09:57:14 提供 Nasdaq GlobeNewswire

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

24 9 2021 15:24:07 提供 Nasdaq GlobeNewswire

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories

14 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

30 8 2021 15:17:19 提供 Nasdaq GlobeNewswire

OPKO Health to Participate in Two Upcoming Investment Conferences

30 8 2021 08:04:49 提供 Nasdaq GlobeNewswire

OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

29 7 2021 15:05:01 提供 Nasdaq GlobeNewswire